Results 51 to 60 of about 1,017,685 (306)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Immunostaining Protocol: P-Smad2 (Xenograft and Mice)

Bio-Protocol, 2014
Metastasis depends on a gene program expressed by the tumor microenvironment upon TGF-beta stimulation. CRC (Colorectal cancer) cell lines did not induce robust stromal TGF-beta responses when injected into nude mice as shown by lack of p-SMAD2 ...
Alexandre Calon, Elisa Espinet, Sergio Palomo-Ponce, Daniele Tauriello, Mar Iglesias, María Céspedes, Marta Sevillano, Cristina Nadal, Peter Jung, Xiang Zhang, Daniel Byrom, Antoni Riera, David Rossell, Ramón Mangues, Joan Massague, Elena Sancho, Eduard Batlle   +16 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

El factor de crecimiento transformante beta como blanco terapéutico Transforming growth factor-beta as a therapeutic target

Salud Pública de México, 2004
El factor de crecimiento transformante beta (TGF-beta) es una familia de proteínas que incluye al TGF-beta, activinas y a la proteína morfogénica de hueso (BMP, por sus siglas en inglés), citocinas que son secretadas y se relacionan estructuralmente en ...
Francisco Javier Gálvez-Gastélum, Ana Soledad Sandoval-Rodríguez, Juan Armendáriz-Borunda   +2 more
doaj  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

FKBP51 increases the tumour‐promoter potential of TGF‐beta

Clinical and Translational Medicine, 2014
Background FKBP51 (FKBP5 Official Symbol) is a large molecular weight component of the family of FK506 binding proteins (FKBP). In recent years, research studies from our laboratory highlighted functions for FKBP51 in the control of apoptosis and ...
Simona Romano, Anna D’Angelillo, Paolo D’Arrigo, Stefania Staibano, Adelaide Greco, Arturo Brunetti, Massimiliano Scalvenzi, Rita Bisogni, Iris Scala, Maria Fiammetta Romano   +9 more
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Biologics: Targets & Therapy, 2008
Peter J O’Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN,
Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al   +5 more
doaj  

TGF beta-mediated expression of TGF beta-activating integrins in SSc monocytes: disturbed activation of latent TGF beta? [PDF]

, 2020
Contains fulltext : 217417.pdf (Publisher’s version ) (Open Access)
Caam, A.P. van, Aarts, J., Ee, T.J. van, Vitters, E.L., Koenders, M.I., Loo, F. van de, Lent, P.L. van, Hoogen, F.H.J. van den, Thurlings, R.M., Vonk, M.C., Kraan, P.M. van der   +10 more
openaire   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source